Is BOLT or BRNS more undervalued in 2026?

CirclFi compares Bolt Biotherapeutics, Inc. (BOLT) and Barinthus Biotherapeutics plc (BRNS) using 13 institutional-grade valuation models. BOLT has a Quality of Company score of 5.9/10 while BRNS scores 6.0/10.

Which is a better buy — BOLT or BRNS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BOLT and BRNS valuations compare?

BOLT at $5.25 and BRNS at $0.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BOLT vs BRNS Valuation Comparison 2026 — Intrinsic Value Analysis

BOLT

Pharmaceutical Preparations

Bolt Biotherapeutics, Inc.

Quality

5.9

out of 10

Value Trap

LOW

Price

$5.25

Last close

Models

9/13

Active

BRNS

Pharmaceutical Preparations

Barinthus Biotherapeutics plc

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.68

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BOLT Fair Value	BOLT Upside	BRNS Fair Value	BRNS Upside
Bayesian DCF	Intrinsic	$0.54	-88.5%	$0.94	+38.4%
First Chicago	Scenario	$3.14	-32.7%	$0.29	-57.0%
ML-RIV	Intrinsic	$17.21	+227.8%	$1.59	+134.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BOLT vs BRNS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BOLT vs BRNS — Which Stock Is More Undervalued?

BRNS scores higher with a 6.0/10 quality rating vs BOLT's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bolt Biotherapeutics, Inc. (BOLT) and Barinthus Biotherapeutics plc (BRNS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BOLT currently trades at $5.25 with a QOC of 5.9/10, while BRNS trades at $0.68 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).